Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 18, 2007

Oxford Genome Sciences Partners with Medarex and Biosite to Enhance Oncology Pipeline

  • Oxford Genome Sciences (OGeS) gained access to Medarex’ fully human antibody technology and also signed on Biosite for initial research.

    Biosite will carry out the early-stage antibody generation for OGeS on this transgenic mouse platform against cancer targets. OGeS will identify these targets using its OGAP® database.

    OGeS will retain the worldwide license to the antibodies generated, and Medarex has the right to receive various fees and royalties. Biosite will receive access to the OGeS diagnostic targets in colorectal and ovarian cancer.

    Under a separate agreement between OGeS and Biosite, Biosite may also establish a companion diagnostic assay on certain programs selected by companies.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »